Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Netrin-1 Promotes Atherosclerosis by Inhibiting the Emigration of Macrophages from Plaques

By LabMedica International staff writers
Posted on 22 Feb 2012
Cardiovascular disease researchers have identified a molecular signal that promotes the blockage of arteries by preventing migration of macrophages away from atherosclerotic plaques.

The signaling molecule is the protein netrin-1. More...
The netrin family is composed mostly of secreted proteins that normally serve as bifunctional signals during development of the embryonic brain. Expressed in the midline of all animals possessing bilateral symmetry, they can act as long or short-range signals during neurogenesis. In order to carry out their functions, netrins interact with specific receptors: DCC or UNC-5 depending on whether they are trying to attract or repel neurons respectively. The C-terminal domain of the netrins is where most of the variation is found between species and it contains different amino acids that allow interaction with specific proteins in extracellular matrix or on cell surface. The differences in terms of structure and function have led to the identifications of several different types of netrins including netrin-1, netrin-3, and netrins-G.

Investigators at the New York University School of Medicine (New York, USA) used fluorescence microscopy techniques to trace the movement of macrophages towards and away from plaques that had formed in arterial tissue taken from mice deficient in the receptor for low-density lipoprotein. Arterial tissues taken from animals genetically engineered to lack macrophage netrin-1expression were also examined.

Results published in the January 8, 2012, online edition of the journal Nature Immunology revealed that acting via its receptor protein, UNC5b, netrin-1 inhibited the migration of macrophages directed by the chemokines CCL2 (chemokine (C-C motif) ligand 2) and CCL19 (chemokine (C-C motif) ligand 19), as well as activation of the actin-remodeling GTPase Rac1 and actin polymerization. Genetically engineered deletion of netrin-1 in macrophages resulted in much less atherosclerosis in mice deficient in the receptor for low-density lipoprotein and promoted the emigration of macrophages from plaques.

The finding that netrin-1 promoted atherosclerosis by retaining macrophages in the artery wall prompted the investigators to conclude that, “Our results establish a causative role for negative regulators of leukocyte migration in chronic inflammation. Local inhibition of such factors may have therapeutic value for the resolution of inflammation in atherosclerosis and other chronic inflammatory diseases.”

Related Links:

New York University School of Medicine




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.